D-0645-2025 Class II Ongoing

Recalled by Ascend Laboratories, LLC — Bedminster, NJ

FDA drug recall D-0645-2025 was initiated by Ascend Laboratories, LLC on Aug 28, 2025 and is designated Class II. Reason for recall: Superpotent drug The recall status is ongoing. Affected quantity: 2,256 bottles.

Recall details

Product Type
Drugs
Report Date
Sep 24, 2025
Initiation Date
Aug 28, 2025
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
2,256 bottles

Product description

Aripiprazole Tablets, USP, 10 mg, 30-count bottles, Rx only, Manufactured by: Alken Laboratories Ltd., INDIA; Distributed by: Ascend Laboratories, LLC, Parsippany, NJ 07054. NDC: 67877-432-03

Reason for recall

Superpotent drug

Distribution pattern

Nationwide in the USA.

Code information

Lot #: 24144162, Exp. Date 09/2027

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0645-2025
openFDA file date
Nov 19, 2026
Loaded by RegDataLab
Nov 20, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Need the full FDA record for Ascend Laboratories, LLC? Ask Claude or ChatGPT with the RegDataLab connector and get every site's inspections, Form 483s, warning letters, recalls and import alerts, each with a link to the FDA source. The API key is free: no card.

Get a free API key

How the connector works

Source: openFDA record for D-0645-2025. Report a data issue: hello@regdatalab.com.